Erschienen in:
16.05.2017 | Endocrine Imaging
“Pseudo-progression” in advanced thyroid cancer in response to kinase inhibitor therapy
verfasst von:
Sina Jasim, Mark A. Nathan, Keith C. Bible
Erschienen in:
Endocrine
|
Ausgabe 1/2017
Einloggen, um Zugang zu erhalten
Excerpt
Lenvatinib is approved for use in patients with radioactive iodine-resistant differentiated thyroid cancer [
1]. Fluorodeoxyglucose (FDG)
-positron emission tomography (PET
) imaging characteristics can be misleading in response to initial therapy; treating providers need to be familiar with the range of therapy-related imaging changes. …